Bioventus (BVS) Cash & Current Investments (2020 - 2025)
Bioventus' Cash & Current Investments history spans 6 years, with the latest figure at $51.2 million for Q4 2025.
- For Q4 2025, Cash & Current Investments rose 23.22% year-over-year to $51.2 million; the TTM value through Dec 2025 reached $51.2 million, up 23.22%, while the annual FY2025 figure was $51.2 million, 23.22% up from the prior year.
- Cash & Current Investments reached $51.2 million in Q4 2025 per BVS's latest filing, up from $42.2 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $140.1 million in Q3 2021 to a low of $22.8 million in Q1 2025.
- Average Cash & Current Investments over 5 years is $51.2 million, with a median of $39.0 million recorded in 2022.
- Peak YoY movement for Cash & Current Investments: soared 80.63% in 2021, then plummeted 75.75% in 2022.
- A 5-year view of Cash & Current Investments shows it stood at $49.2 million in 2021, then plummeted by 38.62% to $30.2 million in 2022, then rose by 22.36% to $37.0 million in 2023, then grew by 12.49% to $41.6 million in 2024, then increased by 23.22% to $51.2 million in 2025.
- Per Business Quant, the three most recent readings for BVS's Cash & Current Investments are $51.2 million (Q4 2025), $42.2 million (Q3 2025), and $32.9 million (Q2 2025).